Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hoursRepros Therapeutics (NASDAQ:RPRX)announces that the European Medicines Agency's advisory group, the Committee for Medicinal Products for Human Use (CHMP), will likely adopt a negative opinion next month in response to its marketing application seeking approval for enclomiphene for the treatment of secondary hypogonadism.Enclomiphene is one of two products in the company's pipeline (Proellex) so the news is a big negative for acquirer Allergan (NYSE:AGN).Shares are off10% after hours on robust volume.Previously:Repros' marketing application for enclomiphene accepted for review in Europe (Oct. 5, 2016)Previously:Allergan to acquire Repros for $0.67 per share(Dec. 12)See all stocks on the move »
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Royalty Pharma Declares Second Quarter 2024 DividendGlobeNewswire
- Royalty Pharma plc (NASDAQ: RPRX) had its price target lowered by analysts at Bank of America Co. from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Royalty Pharma plc (NASDAQ: RPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
RPRX
Sec Filings
- 4/3/24 - Form 144
- 4/3/24 - Form 144
- 4/2/24 - Form 4
- RPRX's page on the SEC website